Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.
A number of other equities analysts have also issued reports on the stock. Weiss Ratings upgraded shares of Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, August 3rd. HC Wainwright initiated coverage on shares of Eikon Therapeutics in a research note on Friday, October 16th. They set a “buy” rating and a $23.00 price target on the stock. Wedbush lowered their price target on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating for the company in a report on Friday, August 14th. Mizuho upgraded shares of Eikon Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 16th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Eikon Therapeutics in a research report on Friday, August 21st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $24.67.
Check Out Our Latest Analysis on EIKN
Eikon Therapeutics Price Performance
Shares of NASDAQ:EIKN opened at $5.98 on Friday. Eikon Therapeutics has a 12 month low of $5.01 and a 12 month high of $17.40. The company’s 50-day moving average price is $7.53 and its two-hundred day moving average price is $10.04. The firm has a market cap of $323.94 million and a P/E ratio of -1.46.
Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($1.59) earnings per share for the quarter, beating the consensus estimate of ($1.74) by $0.15. As a group, equities analysts predict that Eikon Therapeutics will post -7.04 earnings per share for the current fiscal year.
Insider Transactions at Eikon Therapeutics
In other news, major shareholder Group Iv Gp Lp Column purchased 89,200 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were acquired at an average price of $11.56 per share, for a total transaction of $1,031,152.00. Following the completion of the acquisition, the insider directly owned 89,200 shares in the company, valued at approximately $1,031,152. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Institutional Trading of Eikon Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its position in Eikon Therapeutics by 29.0% during the 2nd quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock valued at $55,873,000 after purchasing an additional 962,046 shares during the period. Regents of The University of California bought a new position in shares of Eikon Therapeutics in the 3rd quarter valued at about $5,106,000. State Street Corp grew its position in shares of Eikon Therapeutics by 71.9% during the 3rd quarter. State Street Corp now owns 608,838 shares of the company’s stock worth $4,895,000 after buying an additional 254,745 shares during the period. Parkman Healthcare Partners LLC acquired a new stake in shares of Eikon Therapeutics during the 2nd quarter worth approximately $3,341,000. Finally, Comprehensive Financial Management LLC acquired a new stake in shares of Eikon Therapeutics during the 2nd quarter worth approximately $1,517,000.
About Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company focused on discovering and developing medicines for serious diseases, including cancer. The company uses advanced imaging, computational biology and drug-discovery methods to study how proteins behave in living cells and identify potential therapeutic targets. Founded in 2019 by Roger Perlmutter, a former head of Merck Research Laboratories, Eikon is based in California. Its work is centered on research and development; the company is not known for marketed medicines.
Further Reading
- Five stocks we like better than Eikon Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Eikon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eikon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
